2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
March 8th 2022
Antibody-drug conjugates are innovative and effective therapeutic agents that have transformed the treatment landscape for patients with HER2-positive breast cancer and triple-negative breast cancer.
April 19th 2021
As investigators expand their understanding of the biology of endometrial cancer, doors to new treatment approaches are opening, including the use of a variety of combinations that employ targeted therapies and immunotherapies.
March 25th 2021
As CDK4/6 inhibitors solidify their role as the treatment of choice for patients with hormone receptor–positive, HER2-negative breast cancer, an ongoing clinical challenge remains: distinguishing the appropriate agent.
May 14th 2020
The degree to which nature and nurture affect disease has long been debated in medicine, and it is an issue that esteemed breast cancer researcher and medical oncologist Joyce A. O’Shaughnessy, MD, has been working to unravel for her patients throughout a career that spans more than 30 years.
May 13th 2020
During a recent OncLive Peer Exchange®, a panel of experts in adult and pediatric leukemias provided an update on minimal residual disease testing in acute lymphoblastic leukemia.
May 17th 2010
A novel blood test identifies PAM4 (or clivatuzumab), an antigen that is present in almost 90% of pancreatic cancers and precancers.